Expanded Hemodialysis (HDx) is the next evolution in hemodialysis that brings us a step closer to the natural kidney
Conventional/large middle molecular (500-45,000 Da) uremic toxins have been linked to the development of inflammation, cardiovascular disease (CVD) and other dialysis related comorbidities1-3
CVD is strongly associated with inflammation, atherosclerosis and calcification. ~50% of patients with kidney failure (KF) die from CVD4-6
Traditional high-flux membranes, have limited capability to remove conventional and large middle molecular uremic toxins (up to 45,000 Da)7
The unique design of the Theranova membrane delivers superior removal of conventional/large middle molecules (up to 45,000 Da),1,8-10 compared to high-flux membranes, while selectively retaining essential proteins and maintaining stable albumin levels.8,11,12
HDx therapy showed a significant reduction in hospital days and in-center medication usage, in a retrospective analysis (n=81)13. A Randomized Control Trial (n=171) showed a significant reduction of 45% in all-cause hospitalizations14. Improvement in certain inflammatory markers were observed in select patients (n=41)15.
HDx therapy may improve patient reported kidney disease quality of life outcomes including symptom burden, restless leg syndrome (RLS) criteria uremic pruritus and dialysis recovery time. 8,10,16,17
Simply change the dialyzer membrane to expand clearance
and CHANGE EVERYTHING for your patients.
Watch the video to hear how one dialysis patient's experience with HDx therapy changed her life
See how HDx enabled by Theranova works
Watch the video for more information on Theranova's mechanism of action.
Introducing HDx Talks Education Series
Access our on-demand video library of short (5-15 minutes) modules delivered by experts on topics like:
Innovations like the Theranova membrane that bring us one step closer to the natural kidney1,9,10
Pathological role that conventional/large middle molecular toxins (up to 45,000 Da) play in the development of uremic clinical syndrome
Evidence surrounding clinical effectiveness, safety and efficacy, patient-reported Quality of Life and health economic outcomes related to HDx therapy
Hear from leading experts in Renal Care and Dialysis
Claudio Ronco, MD
University of Padua, Italy
Chris McIntyre, MD
University of Western Ontario, Canada
Ha Tran, MD, NS, FAAP
Baxter International, Inc.
Mary Gellens, MD
Baxter International, Inc.
The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis.
For single use only.
Rx Only. For safe and proper use of these devices refer to the Instructions for Use.